Novo Nordisk's pricing procedures from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, that has accused the company of value gouging, pointing out the stark contrast between U.S. rates and people in Europe and copyright.California biotech behemoth Amgen ditched ideas for an experimental weight loss tablet in May possibly bu